Syndex Bio is a biotechnology platform offering molecular technologies and AI for the diagnosis and treatment of disease.
Syndex Bio has raised $15.5M in total funding. The most recent round was Seed. The last funding was announced in February 2026.
Syndex Bio is headquartered in Cambridge, United Kingdom.
Syndex Bio is a biotechnology platform offering molecular technologies and AI for the diagnosis and treatment of disease.
Syndex Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Syndex Bio — Funding & Investors." VCBacked, February 23, 2026, https://www.vcbacked.co/company/syndex-bio. Accessed September 2, 2026.
VCBacked. (2026). Syndex Bio — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/syndex-bio
{{cite web |title=Syndex Bio — Funding & Investors |url=https://www.vcbacked.co/company/syndex-bio |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated